Silenseed is a development stage biopharmaceutical company that is developing proprietary RNA interference (RNAi)-based cancer drugs and delivery systems designed to effectively penetrate and treat malignant solid tumors. The company’s new second generation drug siRNA used together with the new delivery system, the microparticle product SIL-103 have the potential to be one of the most highly effective treatments for solid tumor cancers. Silexion is focused on the treatment of Locally advanced and borderline resectable Pancreatic Cancer.